Especially, such a treatment is capable of disintegrating pathogenic bacteria in CRC such as Fn, which, more attractively, leads to LPS fragment release as PAMPs for the immune activations, both innate and adaptive, as verified in the following. This evidence concerns the gene FN1 and colorectal carcinoma.